Nature Medicine | Spoonful of Medicine

Patient groups cautiously optimistic about Fabrazyme plant approval

Two-and-a-half years after a virus struck Genzyme’s main production plant—triggering worldwide shortages of Fabrazyme, an enzyme replacement therapy for Fabry’s disease, an illness that afflicts fewer than 10,000 people worldwide—regulators in the US and EU have approved a new manufacturing facility. With the opening of the new plant, Genzyme announced today that all Americans currently taking Fabrazyme (agalsidase beta) and the most severely affected European patients should be up to full dosing by the end of March. 


Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.